Compare BioNano Genomics Inc (BNGO) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Enbridge Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Enbridge Inc trades at $51.57 (market cap $112.62B). The key difference: Enbridge Inc is far larger — about 8244.5× BioNano Genomics Inc's market cap, and Enbridge Inc pays a 5.34% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | ENB | |
|---|---|---|
Market Cap | $13.66M | $112.62B |
Sector | Health | Energy |
52-Week High | $4.92 | $58.04 |
52-Week Low | $1.06 | $45.23 |
Enterprise Value | $16.26M | $196.53B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
ENB trades at $51.51, up 0.23% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend history with 31 consecutive years of increases. Revenue grew to $65.19B in 2025, though net income margin is expected to dip to 7.33% in 2026. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is mixed: robust infrastructure demand and a $41B project backlog support growth, but legal challenges and volatile energy markets pose risks. The stock offers a solid yield and consistent dividend growth, appealing for income investors, yet faces headwinds from regulatory scrutiny and debt levels nearing 49% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
